Form 4: Supernus Pharmaceuticals Executive Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On February 26, 2024, Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, exercised options to purchase 5,000 shares of common stock at a price of $9.13 per share.
- Simultaneously, Bhatt sold 5,000 shares of Supernus common stock at a weighted average price of $30.21, with individual sales ranging from $30.13 to $30.35.
- These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on September 7, 2023.
- Following these transactions, Bhatt directly owns 8,570 shares of Supernus common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There's no indication of positive or negative implications for the company's performance.
Industry Context
Insider transactions are routinely monitored by investors to gauge executive sentiment and potential future performance of the company. A 10b5-1 plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- The use of 10b5-1 trading plans is a common practice among corporate executives to manage their stock sales in a compliant manner.
- Comparing Bhatt's transactions to those of executives at similar pharmaceutical companies (e.g., Teva, Mylan, or Viatris) could provide context on the scale and frequency of insider trading activity.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
- The transactions are unlikely to significantly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 09/07/2023 | Date of adoption of the 10b5-1 trading plan. |
| 03/03/2016 | Initial vesting date of the employee stock option. |
| 02/26/2024 | Date of the transaction (exercise of options and sale of shares). |
| 02/28/2024 | Date of signature of the Form 4 filing. |
| 03/03/2025 | Expiration date of the employee stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.